FDA panel rejects Bystolic for treating heart failure

01/11/2010 | Reuters

An FDA panel recommended against approving Forest Laboratories' hypertension drug Bystolic for treating heart failure, saying clinical data were not sufficient to prove the treatment's safety. Forest President and Chief Operating Officer Larry Olanoff said the company is disappointed but will confer with the agency on possibly adding a label that conveys information about the heart failure study.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX